Drug intelligence / Profile preview

ALID-11

Development stage: Unknown
Lead developer: Allied Biotech
Modality: Small Molecules

Overview

ALID-11 is an investigational pharmaceutical candidate from Allied Corp. being developed for post-traumatic stress disorder and related mental health conditions. Based on the provided context, it is in Phase 1 development and is described as acting through targeted modulation of the 5-hydroxytryptamine receptor 2 pathway and related physiological pathways. The specific active ingredient, exact molecular identity, formulation details, route of administration, and manufacturer have not been clearly disclosed in the provided materials.

Targets

5-HT2 (5-HT2 receptor family)

Beyond the preview

Go deeper on ALID-11.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ALID-11.

Explore the full profile